Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Self-dosing versus fixed-dose pancreatic enzyme replacement in exocrine pancreatic insufficiency
NL-OMON35552Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2011
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of pancreatin in exocrine pancreatic insufficiency (EPI) (2 arms), sponsored by Erasmus MC. Primary endpoint: Fecal fat absorption. Started Oct 2011; status: recruiting.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NL-OMON35552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35552.